SECsense Logo

NLS Pharmaceutics Ltd. 6-K/A Report: Correction on Extraordinary Shareholders’ Meeting Date

$NLSP
Form 6-K/A
Filed on: 2024-12-19
Source
NLS Pharmaceutics Ltd. 6-K/A Report: Correction on Extraordinary Shareholders’ Meeting Date

Here are the key insights extracted from the provided section of the financial report (Form 6-K/A):

  1. Filing Information:
  • The document is an amendment (Amendment No. 1) to Form 6-K, filed by NLS Pharmaceutics Ltd.
  • It was submitted to the SEC on December 19, 2024.
  1. Purpose of the Amendment:
  • The amendment aims to correct a typographical error found in Exhibit 99.1 of the original Form 6-K.
  • Specifically, it clarifies that the record date for the upcoming Extraordinary Shareholders’ Meeting is December 16, 2024.
  1. Extraordinary Shareholders' Meeting:
  • The meeting is scheduled for January 7, 2025.
  • Only shareholders who hold common and/or preferred shares of the Registrant as of the close of business on December 16, 2024, will be eligible to vote at the meeting and any adjournments.
  1. Registration Statements:
  • The report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3, with several specific file numbers referenced.
  1. Company Details:
  • NLS Pharmaceutics Ltd. is located at The Circle 6, 8058 Zurich, Switzerland.
  • The document is signed by the CEO, Alexander C. Zwyer, confirming its validity and compliance with SEC requirements.
  1. Regulatory Framework:
  • The filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, indicating it is compliant with U.S. securities laws for foreign private issuers.

Overall, this document primarily serves to correct the record date for the upcoming shareholder meeting, ensuring that shareholders are properly informed about their voting eligibility.